Trump Executive Order Accelerates Psychedelic Drug Approvals, Triggering Sector Rally

Shares of companies specializing in psychedelic-based therapies experienced a dramatic rally on Monday following a presidential executive order aimed at accelerating research and patient access. The move has provided a significant catalyst for biotech firms facing lengthy regulatory hurdles. The order specifically targets the regulatory bottleneck at the U.S. Food and Drug Administration (FDA). By directing the agency to issue expedited review vouchers for therapies with 'breakthrough' designations, the administration is effectively slashing the review window from the standard six-to-ten months down to just one to two months. The market response was immediate and aggressive. Compass Pathways saw its shares spike by as much as 53%, while AtaiBeckley and GH Research surged 37% and 34%, respectively. Definium Therapeutics also posted gains of 16%. The broader sector, tracked by the AdvisorShares Psychedelics ETF (PSIL), climbed 20%, reaching its highest intraday level since July 2023. This regulatory shift is particularly impactful for firms like Compass Pathways, AtaiBeckley, and Definium, all of which currently hold breakthrough status for their respective therapies. By reducing the time-to-market risk, the order significantly alters the valuation profile for these high-volatility healthcare assets.